Although gene expression quantification technologies such as Oncotype DX have been shown to have predictive value in terms of BC outcomes [37,38,39], our study demonstrated that IHC-PIDs could be used as a complementary diagnostic tool to predict the response to ET in HR-positive HER2-negative breast cancer. This evidence concerns the gene ERBB2 and breast cancer.